Furmonertinib (Furmonertinib Mesylate) is a third-generation EGFR-TKI inhibitor primarily indicated for the treatment of non-small cell lung cancer (NSCLC), and it has now been approved for marketing in certain countries and regions. The National Medical Products Administration (NMPA) of China approved its marketing in March 2021 for the treatment of patients with locally advanced or metastatic NSCLC who have experienced disease progression following prior EGFR-TKI therapy and harbor the EGFR T790M mutation. This agent exerts its therapeutic effect by selectively inhibiting EGFR sensitive mutations and the T790M resistance mutation.
Key Information Notes
1. Approval Status
The domestic marketing approval of furmonertinib in China was based on the results of a multicenter Phase Ⅱ clinical trial (Study FURLONG), which demonstrated significant efficacy of the agent in patients with the EGFR T790M mutation, with an Objective Response Rate (ORR) of 74.1% and a median Progression-Free Survival (mPFS) of 9.6 months. Initially, the drug was approved with conditional approval, requiring further clinical studies to verify its long-term efficacy and safety.
2. Indications and Usage Restrictions
Current Indication: Restricted to second-line therapy, i.e., for EGFR-mutant patients who develop the T790M resistance mutation after treatment with first/second-generation EGFR-TKIs (e.g., Gefitinib, Erlotinib).
Expansion Research: Phase Ⅲ clinical trials for first-line therapy (e.g., in combination with chemotherapy or other targeted agents) are underway, but no new indications have been approved yet.
3. Drug Access and Medical Insurance Coverage
Furmonertinib has been included in the 2023 National Medical Insurance Catalog of China, with the medical insurance reimbursement scope consistent with its approved indication.
The specific price and reimbursement rate may vary according to regional policy regulations, and inquiries should be made in conjunction with local medical insurance policies.
4. Adverse Reactions and Safety Profile
Common adverse effects include diarrhea, rash, and oral mucositis, most of which are Grade 1-2 (mild to moderate). Clinical data show that the drug is well-tolerated, with a low incidence of serious adverse reactions (e.g., interstitial lung disease) at approximately 2.6%. However, close monitoring is still required during the course of treatment.
Important Considerations
Necessity of Genetic Testing: Confirmation of the EGFR T790M mutation status via tissue or blood testing is mandatory before administration.
Resistance Mechanisms: Some patients may experience treatment failure due to acquired resistance (e.g., C797S mutation), and subsequent treatment regimens need to be adjusted based on the type of resistance.
Exploration of Combination Therapy: Studies suggest that furmonertinib combined with anti-angiogenic agents or chemotherapy may delay the development of drug resistance, but such regimens have not yet become the standard of care.
Summary
As a third-generation EGFR-TKI, furmonertinib provides an important therapeutic option for specific patients with non-small cell lung cancer. Its efficacy and safety have been validated by clinical studies, but its use must strictly comply with the approved indications and medication norms. The specific treatment plan for a patient should be determined comprehensively based on genetic testing results, prior treatment history, and the doctor’s recommendations.
